The global Influenza Diagnostics Market is projected to grow at a CAGR of 6.5% from 2024 to 2031. The market value is expected to increase from USD XX billion in 2024 to USD YY billion by 2031.
North America currently dominates the market, followed by Europe and Asia-Pacific. Key metrics include increasing incidence of influenza, growing awareness about early diagnosis, and technological advancements in diagnostic techniques.
The market is continuously expanding due to the rising global incidence of influenza, greater investments in healthcare infrastructure, and a growing emphasis on preventive healthcare. The development of rapid and accurate diagnostic tests, as well as the integration of artificial intelligence into diagnostic platforms, are all contributing to market expansion.
Market Trend: Shift towards multiplexed molecular diagnostics
The influenza diagnostics market is rapidly shifting towards multiplexed molecular diagnostic methods. These sophisticated diagnostics can detect and distinguish between a variety of respiratory diseases, including diverse influenza virus strains, in a single experiment. This advancement is being driven by the need for more comprehensive and effective diagnostic tools, especially in the presence of co-circulating respiratory diseases. For example, in 2023, a leading diagnostic company introduced a new multiplexed PCR panel that can detect and discriminate between 20 different respiratory illnesses, including influenza A and B, in less than 45 minutes. This trend is expected to accelerate as healthcare practitioners work to improve diagnostic accuracy and reduce turnaround times, particularly during peak respiratory infection seasons.
Market Driver: Increasing prevalence of influenza and emerging viral strains
The rising incidence of influenza and the emergence of novel virus strains are important drivers of the influenza diagnostics sector. According to the World Health Organisation, seasonal influenza epidemics cause 3 to 5 million episodes of severe illness and around 290,000 to 650,000 respiratory deaths worldwide each year. The continued evolution of influenza viruses, as well as the risk of pandemic outbreaks, necessitate robust diagnostic abilities. For example, the COVID-19 pandemic has boosted awareness of respiratory infections and increased investment in diagnostic services. A global study conducted in 2023 revealed a 30% increase in influenza testing volumes compared to pre-pandemic levels, indicating a greater emphasis on respiratory virus detection. The demand for improved influenza diagnostic technology is significant, driven by the need for prompt and accurate diagnosis to guide treatment options and inform public health responses.
Market Restraint: Variability in test sensitivity and specificity
One of the most serious difficulties in the influenza diagnostics industry is the disparity in sensitivity and specificity between different diagnostic assays. While molecular tests like RT-PCR are extremely accurate, rapid influenza diagnostic tests (RIDTs) may be less sensitive, resulting in false-negative results. A 2023 study found that the sensitivity of multiple RIDTs varied from 50% to 70% depending on the influenza strain and viral burden. This unpredictability can lead to misdiagnoses, jeopardising patient treatment and public health measures. Furthermore, sample collection timing and influenza incidence in the community can affect diagnostic test performance. Addressing these accuracy issues through improved test designs and clear test selection and interpretation guidelines is crucial for market expansion and efficient influenza management.
Molecular Diagnostic Tests dominate the Influenza Diagnostics market:
Molecular Diagnostic Tests are the largest segment in the influenza diagnostics industry, accounting for over 55% of the market share. This dominance is owing to their high sensitivity and specificity in detecting influenza viruses, as well as their ability to provide data quickly. Molecular testing, particularly RT-PCR-based tests, has emerged as the gold standard for influenza diagnosis due to their high accuracy and ability to detect viral genetic material at low concentrations.
Recent advances in molecular diagnostics include the introduction of speedier and more automated technology. For example, in 2023, a large diagnostics company launched a breakthrough point-of-care molecular test that can detect influenza A and B in just 13 minutes, significantly decreasing the time to diagnosis. These breakthroughs have accelerated the use of molecular diagnostics in a wide range of healthcare settings, from large hospitals to small clinics.
The molecular diagnostics market is also benefiting from the increased focus on influenza strain surveillance and the need for subtyping to guide antiviral treatment options. According to industry experts, the use of molecular diagnostic tests for influenza increased by 20% in 2023 compared to the previous year, with especially strong growth in outpatient settings. This trend is expected to continue as healthcare providers strive to improve the accuracy and timeliness of influenza diagnosis.
North America leads the global Influenza Diagnostics market:
North America now accounts for more than 40% of the worldwide influenza diagnostics market. This good position is mostly due to the region's superb healthcare infrastructure, extensive awareness of influenza prevention and management, and significant investments in diagnostic technologies.
The United States, in particular, is at the forefront of influenza diagnostic use and innovation. The Centres for Disease Control and Prevention (CDC) oversees the country's robust influenza monitoring system, which creates a high need for diagnostic tests. Furthermore, the presence of large diagnostics companies and research institutions in the region contributes to continued technological advances in influenza testing.
Recent news reports have highlighted ongoing efforts to improve influenza diagnostic skills in North America. In 2023, the US Food and Drug Administration (FDA) granted emergency use clearance for a groundbreaking home-based molecular test for influenza, showing a growing trend towards decentralised testing. This effort highlights the region's commitment to improving access to reliable influenza tests.
Key numbers show North America's dominance in the influenza diagnostics business. According to our analysis, North America accounted for more than ~45% of global influenza diagnostic test sales in 2023. Furthermore, the number of influenza tests in the region has increased by 15% year on year as a result of increased awareness and enhanced testing infrastructure.
The North American market has been particularly active in developing novel applications for influenza diagnostics. In 2023, a cooperation between a leading US institution and a biotechnology business resulted in the development of a breakthrough CRISPR-based diagnostic platform for rapid influenza detection, cementing North America's reputation as an innovation hotspot in this field.
The influenza diagnostics industry is distinguished by the presence of both established rivals and an increasing number of innovative start-ups. To maintain their competitive advantage, key businesses prioritise product innovation, strategic collaborations, and worldwide expansion.
Leading companies in the field have showed strong financial performance, with several claiming annual revenue growth rates of 8-10% for their influenza diagnostics divisions. Market leaders frequently allocate 10-12% of their revenue to R&D, proving the value of innovation in this dynamic field.
The competitive landscape has recently changed towards the development of multiplex testing systems that can detect many respiratory pathogens at the same time. Businesses are also investing in artificial intelligence and machine learning to increase the accuracy and speed of test interpretation.
In terms of market share, the top five companies control almost 65% of the global influenza diagnostics market. However, the market is seeing new entrants, particularly companies that specialise in molecular diagnostics and point-of-care testing, which is expected to boost competition in the coming years.
Partnerships between diagnostic corporations and healthcare providers or research institutes are becoming more common, with several high-profile collaborations announced in the past year. These agreements aim to speed up the development and clinical validation of novel diagnostic technologies while also broadening market reach.
Advances in CRISPR-based diagnostics, the creation of AI-powered diagnostic platforms, and the integration of diagnostics with digital health technologies are all predicted to have an impact on the competitive landscape in the future. Companies who can effectively navigate these changes while providing innovative, cost-effective solutions will have a significant competitive advantage in the market.
The influenza diagnostics sector is at a critical juncture, poised for substantial growth and innovation in the next years. One of the most exciting trends we've noticed is the incorporation of influenza diagnostics into bigger respiratory pathogen testing platforms. This combination has the potential to revolutionise the way we diagnose respiratory infections by introducing more extensive and efficient testing procedures.
Another trend to watch is the increased emphasis on decentralised and home-based testing solutions. The COVID-19 pandemic has accelerated the development and adoption of self-testing technologies, and we anticipate that this trend will spread to influenza diagnostics, potentially altering the landscape of influenza surveillance and management.
The application of big data and artificial intelligence to improve diagnostic accuracy and forecasting skills is also quite promising. As diagnostic platforms generate large amounts of data, we foresee the development of more complicated algorithms capable of improving test interpretation, predicting outbreak trends, and directing public health interventions.
Finally, we predict increased collaboration between diagnostic companies, healthcare providers, and public health groups. These collaborations will be crucial in developing more effective influenza surveillance systems, expanding access to testing in underserved areas, and ensuring rapid response capabilities in the case of future pandemic threats.
Roche Diagnostics
Abbott Laboratories
Thermo Fisher Scientific
Quidel Corporation
Hologic, Inc.
Becton, Dickinson and Company
Meridian Bioscience, Inc.
bioMérieux SA
Luminex Corporation
Siemens Healthineers
In December 2024, Roche Diagnostics unveiled a new high-throughput molecular diagnostic system capable of processing up to 1000 influenza samples per day.
Abbott Laboratories established a strategic partnership with a large pharmacy chain in October 2024 to provide rapid influenza testing services in 5000 locations across the United States.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope & Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking -- Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies list by Country) (Premium)
5. COMPANY PROFILES
5.1. Roche Diagnostics
5.2. Abbott Laboratories
5.3. Thermo Fisher Scientific
5.4. Quidel Corporation
5.5. Hologic, Inc.
5.6. Becton, Dickinson and Company
5.7. Meridian Bioscience, Inc.
5.8. bioMérieux SA
5.9. Luminex Corporation
5.10. Siemens Healthineers (*LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Shift towards multiplexed molecular diagnostics
6.1.2. Increasing focus on decentralized and home-based testing
6.1.3. Integration of AI and big data in diagnostic platforms
6.2. Market Drivers
6.2.1. Increasing prevalence of influenza and emerging viral strains
6.2.2. Growing awareness about early diagnosis
6.2.3. Technological advancements in diagnostic techniques
6.3. Market Restraints
6.3.1. Variability in test sensitivity and specificity
6.3.2. High cost of molecular diagnostic tests
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY TEST TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
7.1. Traditional Diagnostic Tests
7.2. Molecular Diagnostic Tests
8. BY END USER (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
8.1. Hospitals & Clinics
8.2. Diagnostic Laboratories
8.3. Point-of-Care Testing
9. BY TECHNOLOGY (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
9.1. RT-PCR
9.2. RIDT (Rapid Influenza Diagnostic Tests)
9.3. Cell Culture
9.4. Others
10. BY INFLUENZA TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
10.1. Type A
10.2. Type B
10.3. Type C
11. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
11.1. North America
11.1.1. United States
11.1.2. Canada
11.1.3. Mexico
11.2. South America
11.2.1. Brazil
11.2.2. Argentina
11.2.3. Rest of South America
11.3. Europe
11.3.1. Germany
11.3.2. United Kingdom
11.3.3. France
11.3.4. Italy
11.3.5. Spain
11.3.6. Russia
11.3.7. Rest of Europe
11.4. Asia-Pacific
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia
11.4.5. South Korea
11.4.6. Rest of Asia-Pacific
11.5. Middle-East
11.5.1. UAE
11.5.2. Saudi Arabia
11.5.3. Turkey
11.5.4. Rest of Middle East
11.6. Africa
11.6.1. South Africa
11.6.2. Egypt
11.6.3. Rest of Africa
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
By Test Type:
Traditional Diagnostic Tests
Molecular Diagnostic Tests
By End User:
Hospitals & Clinics
Diagnostic Laboratories
Point-of-Care Testing
By Technology:
RT-PCR
RIDT (Rapid Influenza Diagnostic Tests)
Cell Culture
Others
By Influenza Type:
Type A
Type B
Type C
By Region:
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511
